pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Approval · news · pharmadog
← back to Approval
News · Approval
1,551
stories
Oct 16, 26
China looks to ban foreign acquisitions of critical biopharma platforms
fiercebiotech
Oct 16, 26
FDA issues early alert for Edwards Lifesciences’ mitral valve delivery system after reported death, injury
fiercebiotech
Oct 15, 26
Trump administration advances plan for peptide drugs favored by RFK Jr.
stat
Oct 15, 26
Merck and Moderna have ‘lot of exploring to do’ after initial cancer vaccine success
stat
Oct 15, 26
Mass. lawmaker Auchincloss favors boosting U.S. biotech over targeting China
stat
Oct 15, 26
Belgian startup revives Galapagos CAR-T research
biopharma dive
Oct 15, 26
STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer
stat
Oct 15, 26
FDA ‘reset’ continues with new plan for reviewing rare disease drugs
biopharma dive
Oct 15, 26
FDA's latest rare disease framework seeks to prioritize consistency in flexibility
biospace
Oct 15, 26
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment
biospace
Oct 15, 26
Compass Pathways CEO: Psychedelics company will ‘go slow before we go fast’
stat
Oct 14, 26
Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit
biopharma dive
Oct 14, 26
FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development
fda press
Oct 14, 26
FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
fda press
Oct 14, 26
Verastem cancer drug shows early promise in small study
biopharma dive
Oct 14, 26
STAT+: FDA adcomm members’ ties to industry under scrutiny
stat
Oct 14, 26
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
biospace
Oct 14, 26
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
biospace
Oct 14, 26
Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear unconvinced
fiercebiotech
Oct 14, 26
Why OMass’ $310M series C marks ‘fantastic milestone’ on journey to become ‘Britain’s Big Biotech’
fiercebiotech
Oct 13, 26
Novartis quietly returns a key antibiotic to US market
endpoints
Oct 13, 26
BioNTech mRNA cancer immunotherapy misses first objective in key study
biopharma dive
Oct 13, 26
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment
biospace
Oct 13, 26
Analysts eye RevMed’s pancreatic cancer launch, Merck’s data blitz for Q3 earnings
biospace
Oct 13, 26
STAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
stat
Oct 13, 26
Study pushes for greater adoption of a cloud-based regulatory environment
raps
Oct 12, 26
Asahi Kasei lands approval for new HSV treatment
endpoints
Oct 12, 26
Bristol Myers dips on ‘confounding’ lung drug results
biopharma dive
Oct 12, 26
BMS’ Phase 3 win for lung drug clouded by high-dose miss
biospace
Oct 12, 26
RevMed's Rasonque gets a subtype data asterisk, but analysts remain bullish
biospace
← prev
page 13 of 52
next →